XML 68 R57.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information - Sales and Earnings (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Segment Reporting Information [Line Items]        
Net Sales to External Customers $ 11,369 $ 10,635 $ 32,869 $ 30,976
Cost of Products Sold (5,075) (4,698) (14,397) (13,764)
Research and Development (766) (713) (2,207) (2,095)
Selling, General and Administrative (3,051) (2,895) (9,203) (8,790)
Operating Earnings 2,057 1,859 5,802 4,914
Amortization of Intangible assets $ (420) $ (470) $ (1,260) $ (1,413)
Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag Other, net (b) Other, net (b) Other, net (b) Other, net (b)
Earnings before Taxes $ 2,180 $ 1,940 $ 6,108 $ 4,983
Annual share-based awards recognized in first quarter (as a percent)     45.00% 45.00%
Operating Segments        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 11,365 10,631 $ 32,857 $ 30,965
Cost of Products Sold (4,994) (4,680) (14,205) (13,656)
Research and Development (709) (672) (2,036) (1,926)
Selling, General and Administrative (2,682) (2,516) (8,044) (7,517)
Operating Earnings 2,980 2,763 8,572 7,866
Operating Segments | Established Pharmaceuticals        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 1,511 1,406 4,154 3,926
Cost of Products Sold (714) (644) (1,914) (1,819)
Research and Development (42) (46) (127) (131)
Selling, General and Administrative (364) (336) (1,078) (1,014)
Operating Earnings 391 380 1,035 962
Operating Segments | Nutritionals        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 2,153 2,066 6,511 6,284
Cost of Products Sold (1,223) (1,151) (3,502) (3,387)
Research and Development (55) (53) (161) (158)
Selling, General and Administrative (515) (550) (1,676) (1,677)
Operating Earnings 360 312 1,172 1,062
Operating Segments | Diagnostics        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 2,253 2,412 6,480 6,821
Cost of Products Sold (1,290) (1,280) (3,666) (3,671)
Research and Development (150) (165) (455) (482)
Selling, General and Administrative (413) (409) (1,228) (1,206)
Operating Earnings 400 558 1,131 1,462
Operating Segments | Medical Devices        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 5,448 4,747 15,712 13,934
Cost of Products Sold (1,767) (1,605) (5,123) (4,779)
Research and Development (462) (408) (1,293) (1,155)
Selling, General and Administrative (1,390) (1,221) (4,062) (3,620)
Operating Earnings 1,829 1,513 5,234 4,380
Other        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 4 4 12 11
Reconciling Items        
Segment Reporting Information [Line Items]        
Corporate functions and plan benefit costs (84) (140) (177) (286)
Net interest expense (44) (51) (143) (170)
Share-based compensation (120) (117) (551) (562)
Amortization of Intangible assets (420) (470) (1,260) (1,413)
Other, net $ (132) $ (45) $ (333) $ (452)